UPDATE 1-Novo diabetes drug cuts heart risks by 13 pct in trial


The logo of Danish multinational pharmaceutical company Novo Nordisk is pictured on the facade of a production plant in Chartres, north-central France, April 21, 2016. Novo Nordisk's top-selling diabetes drug Victoza cut the risk of heart attack, stroke and cardiovascular death by 13 percent in a closely watched study that may encourage wider use of the blockbuster injectable medicine.



from Biotech News